Your browser doesn't support javascript.
loading
TOTUM-63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial.
Sirvent, Pascal; Chavanelle, Vivien; Otero, Yolanda F; Bargetto, Maxime; Le Joubioux, Florian; Boisseau, Nathalie; Maugard, Thierry; Cazaubiel, Murielle; Pereira, Bruno; Guigas, Bruno; Hadjadj, Samy; Peltier, Sebastien L; Marette, André; Bard, Jean-Marie.
Afiliação
  • Sirvent P; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Chavanelle V; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Otero YF; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Bargetto M; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Le Joubioux F; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Boisseau N; Laboratoire AME2P, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Maugard T; CRNH Auvergne, CRNH, Clermont-Ferrand, France.
  • Cazaubiel M; Equipe BCBS (Biotechnologies et Chimie des Bioressources pour la Santé), La Rochelle Université, UMR CNRS 7266 LIENSs, La Rochelle, France.
  • Pereira B; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Guigas B; CHU Clermont-Ferrand, Délégation à la Recherche Clinique et à l'Innovation, Clermont-Ferrand, France.
  • Hadjadj S; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
  • Peltier SL; Département d'Endocrinologie, Diabétologie et Nutrition, l'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.
  • Marette A; Valbiotis R&D Center, Valbiotis, Perigny, France.
  • Bard JM; Quebec Heart and Lung Institute, Department of Medicine, Faculty of Medicine, Laval University, Quebec, Canada.
Diabetes Obes Metab ; 24(12): 2331-2340, 2022 12.
Article em En | MEDLINE | ID: mdl-35837981
ABSTRACT

AIM:

The plant-based polyphenol-rich extract TOTUM-63 improves glucose homeostasis in various preclinical models of obesity and type 2 diabetes (T2D). A pilot exploratory study showed that TOTUM-63 has good safety and tolerability profiles, and beneficial effects on postprandial glucose control in healthy individuals with overweight. The aim of this study was to assess the effects of TOTUM-63 on glycaemic control in individuals with prediabetes or early stage newly-diagnosed T2D (which does not require pharmacological treatment). MATERIALS AND

METHODS:

This study was a multicentre, randomized, double-blind, placebo-controlled trial. Individuals with prediabetes or early stage newly-diagnosed T2D and with overweight/abdominal obesity received TOTUM-63 (5 g/day) or placebo for 6 months. The primary outcome was the change in fasting blood glucose.

RESULTS:

Fifty-one participants (age 57.1 ± 10 years; body mass index 31.3 ± 5.7 kg.m2 ; 35 women and 16 men) completed the study (n = 38 TOTUM-63, n = 13 placebo). After 6 months, blood glucose concentration after fasting and after the 2-h oral glucose tolerance test was reduced in the TOTUM-63-treated group compared with the placebo group (placebo-corrected difference between baseline and month 6 -0.71 mmol/L, p < .05, and -1.93 mmol/L, p < .05, respectively). TOTUM-63 was safe and well tolerated and significantly reduced body weight gain (-1.9 kg; p < .05), waist circumference (-4.5 cm; p < .001), circulating triglycerides (-0.54 mmol/L; p < .01) and low-density lipoprotein-cholesterol (-0.38 mmol/L; p < .05) compared with placebo.

CONCLUSIONS:

TOTUM-63 lowered fasting blood glucose in participants with impaired fasting glycaemia and glucose intolerance. Moreover, TOTUM-63 showed a good safety and tolerability profile and improved several metabolic syndrome features. Therefore, TOTUM-63 is a promising candidate for T2D prevention.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Pré-Diabético / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Pré-Diabético / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França